Quantbot Technologies LP Relmada Therapeutics, Inc. Transaction History

Quantbot Technologies LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	SELL	$2.48 - $3.79 $567 - $867	-229 Reduced 13.12%	1,516 $4,000
Q2 2023 Aug 08, 2023	BUY	$2.22 - $3.54 $250 - $400	113 Added 6.92%	1,745 $4,000
Q1 2023 May 12, 2023	SELL	$2.24 - $4.76 $10,115 - $21,496	-4,516 Reduced 73.45%	1,632 $3,000
Q4 2022 Feb 13, 2023	BUY	$2.17 - $35.84 $13,341 - $220,344	6,148 New	6,148 $21,000
Q2 2022 Aug 09, 2022	SELL	$16.5 - $30.34 $18,150 - $33,374	-1,100 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$16.72 - $26.99 $6,972 - $11,254	-417 Reduced 27.49%	1,100 $29,000
Q4 2021 Feb 11, 2022	SELL	$16.93 - $26.82 $32,167 - $50,958	-1,900 Reduced 55.6%	1,517 $34,000
Q3 2021 Nov 09, 2021	BUY	$21.86 - $34.77 $74,695 - $118,809	3,417 New	3,417 $89,000

5.42M

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $62.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.